Pharmacological regulation of blood glucose levels in non-insulin- dependent diabetes mellitus

Archives of Internal Medicine

Volumn 157, Issue 8, 1997, Pages 836-848

  Bressler, Rubin ^a,b   Johnson, David G ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETOHEXAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; METFORMIN; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; TROGLITAZONE;

BODY FAT; DRUG EFFECT; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HORMONE ACTION; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; LIVER METABOLISM; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

EID: 0031396662     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.8.836     Document Type: Review

References (234)

1. Harris MI, Hadden WC, Knowler WC, et al. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population ages 20-74 years. Diabetes. 1987;136:523-534.
2. King H, Rewers M. WHO Ad Hoc Diabetes Reporting Group: global estimates for prevalence of diabetes mellitus and impaired glucose tolerance. Diabetes Care. 1993;16:157-177.
3. DeFronzo RA. The triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes. 1988;37:667-687.
4. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care. 1992;15:318-368.
5. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin dependent diabetes mellitus. N Engl J Med. 1993;329:1988-1992.
6. Yki-Harvinsen H. Pathogenesis of non-insulin dependent diabetes mellitus. Lancet. 1994;343: 91-95.
7. Pimenta W, Korytkowski M, Mitra A, et al. Pancreatic β-cell dysfunction as the primary genetic lesion in NIDDM. JAMA. 1995;273:1855-1861.
8. Weir GC. Which comes first in non-insulin dependent diabetes mellitus: insulin resistance or β-cell failure? both come first. JAMA. 1995; 273:1878-1879.
9. Vaag A, Henriksen JE, Madsbad S, et al. Insulin secretion, insulin action and hepatic glucose production in identical twins discordant for non-insulin dependent diabetes mellitus. J Clin Invest. 1995;95:690-698.
10. Bogardus C, Lillioja S, Nyomba BL, et al. Distribution of in vivo insulin action in Pima Indians as a mixture of three normal distributions. Diabetes. 1989;38:1423-1432.
11. Warran JH, Martin BC, Krolewski AS, et al. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990;113:909-915.
12. Taylor S, Accilli D, Imai Y. Insulin resistance or insulin deficiency: which is the primary cause of NIDDM? Diabetes. 1994;43:735-740.
13. Saad MF, Knowler WC, Pettitt DJ, et al. A two step model for development of non-insulin dependent diabetes. Am J Med. 1991;90:229-235.
14. Sicree R, Zimmet PZ, King HOM, et al. Plasma insulin response among Naurvans: prediction of deterioration in glucose tolerance over 6 years. Diabetes. 1987;36:179-186.
15. Bruce DG, Chisholm DJ, Storlien LH, et al. Physiological importance of deficiency in early prandial insulin secretion in NIDDM. Diabetes. 1988; 37:736-744.
16. Hamman R. Genetic and environmental determinants of non-insulin dependent diabetes mellitus (NIDDM). Diabetes Metab Rev. 1992;8:287-338.
17. O'Dea K. Obesity and diabetes in 'the land of milk and honey.' Diabetes Metab Rev. 1992;8: 373-388.
18. Kriska AM, Bennett PH. An epidemiological perspective of the relationship between physical activity and NIDDM: from activity assessment to intervention. Diabetes Metab Rev. 1992;8: 355-372.
19. Tuomilehto J, Knowler WC, Zimmet P. Primary prevention of non-insulin dependent diabetes mellitus. Diabetes Metab Rev. 1992;8: 339-353.
20. Bressler P, DeFronzo RA. Drugs and diabetes. Diabetes Rev. 1994;2:53-84.
21. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin dependent diabetes mellitus: contributions of excessive glucose production and impaired tissue glucose uptake. Metabolism. 1989;38:387-395.
22. Ferrannini E, Simonson DC, Katz LD, et al. The disposal of an oral glucose load in patients with non-insulin dependent diabetes. Metabolism. 1988;37:79-85.
23. Mitrakou A, Kelley D, Veneman T, et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes. 1990;39:1381-1390.
24. Leahy JL, Cooper HE, Deal DA, et al. Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion: a study in normal rats using chronic in vivo glucose infusions. J Clin Invest. 1986;77:908-915.
25. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990;13:610-630.
26. Kannel WB, McGes DL. Diabetes and cardiovascular disease: The Framingham Study. JAMA. 1979;241:2035-2038.
27. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987;3:463-524.
28. Chait A, Bierman EL. Pathogenesis of macrovascular disease in diabetes. In: Kahn CR, Weir GC, eds. Joslin's Diabetes Mellitus. 13th ed. Philadelphia, Pa: Lea & Febiger; 1994:648-664.
29. Howard BV, Howard WJ. The pathophysiology and treatment of lipid disorders in diabetes mellitus. In: Kahn CR, Weir GC, eds. Joslin's Diabetes Mellitus. 13th ed. Philadelphia, Pa: Lea & Febiger; 1994:372-396.
30. Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res. 1987;28:613-628.
31. Barakat HA, Carpenter JW, McLendon VD, et al. Influence of obesity, impaired glucose tolerance, and NIDDM on LDL structure and composition: possible link between hyperinsulinemia and atherosclerosis. Diabetes. 1990; 39:1527-1533.
32. Chen YDI, Jeng CY, Reaven GM. HDL metabolism in diabetes. Diabetes Metab Rev. 1987;3: 653-668.
33. Dunn FL. Treatment of lipid disorders in diabetes mellitus. Med Clin North Am. 1988;72: 1379-1398.
34. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaced syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-194.
35. Gerich JE. Oral hypoglycemic agents. N Engl J Med. 1989;321:1231-1245.
36. Melander A, Bitzen P-O, Faber O, et al. Sulphonylurea antidiabetic drugs: an update of their clinical pharmacology and rational therapeutic use. Drugs. 1989;37:58-72.
37. Marchetti P, Navalesi R. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents: an update. Clin Pharmacokinet. 1989;16:100-128.
38. Jackson JE, Bressler R. Clinical pharmacology of sulfonylurea hypoglycemic agents, I and II. Drugs. 1981;22:211-245, 295-320.
39. Malaisse WJ, Lebrun P. Mechanism of sulfonylurea induced insulin release. Diabetes Care. 1990;13(suppl 3):9-17.
40. Pfeifer MA, Halter JB, Judzewitsch RG, et al. Acute and chronic effect of sulfonylurea drugs on pancreas islet function in man. Diabetes Care. 1984;7(suppl 1):25-34.
41. Houssay BA, Penhos JC. Action of the hypoglycemic sulfonyl compounds in hypophysectomized adrenalectomized and depancreatized animals. Metabolism. 1958;5:727-732.
42. Mirsky IA, Lerisutti G, Jinks R. Ineffectiveness of sulfonylureas in alloxan diabetic rats. Proc Soc Exp Biol Med. 1956;91:475-477.
43. Kolterman OG, Gray RX, Shapiro G, et al. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Diabetes. 1984;33: 346-354.
44. Nelson TY, Gaines KL, Rajan AS, et al. Increased cytosolid calcium: a signal for sulfonylurea-stimulated insulin release from beta cells. J Biol Chem. 1987;262:2608-2612.
45. Boyd AE III. Sulfonylurea receptors, ion channels, and fruit flies. Diabetes. 1988;37:847-850.
46. Gaines KL, Hamilton S, Boyd AE III. Characterization of the sulfonylurea receptor on beta cell membranes. J Biol Chem. 1988;263:2589-2592.
47. Aguilar-Brywn L, Nichols CG, Wechsler SW, et al. Cloning of the β cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science. 1995;268:423-426.
48. Thomas PM, Cole GJ, Wohllk N, et al. Mutations in the sulfonylureas receptor gene in familial persistant hyperinsulinemic hypoglycemia of infancy. Science. 1995;268:426-429.
49. Wollheim CB, Biden TJ. Signal transduction in insulin secretion: comparison between fuel stimuli and receptor agonists. Ann N Y Acad Sci. 1986; 488:317-333.
50. Yalow RS, Black H, Villazon M, et al. Comparison of plasma insulin levels following administration of tolbutamide and glucose. Diabetes. 1968;9:356-362.
51. Lebovitz H. Oral hypoglycemic agents. In: Kahn CR, Weir GC, eds. Joslin's Diabetes Mellitus. 13th ed. Philadelphia. Pa: Lea & Febiger; 1994: 508-529.
52. Sartor G, Ursing D, Nilsson-Ehle P, et al. Lack of primary effect of sulphonylurea (glipizide) on plasma lipoproteins and insulin action in former type I diabetics with attenuated insulin secretion. Eur J Clin Pharmacol. 1987;33:279-282.
53. Lebovitz HE, Melander A. Sulfonylureas: basic and clinical aspects. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P. eds. International Textbook ot Diabetes Mellitus. London, England: Wiley Bros; 1992:745-772.
54. Sartor G, Melander A, Schersten B, et al. Influence of food and age on the single dose kinetics and effects of tolbutamide and chlorpropamide. Eur J Clin Pharmacol. 1980;17:285-293.
55. Antal EJ, Gillespie WR, Phillips JP, et al. The effect of food on the bioavailability and pharmacodynamics of tolbutamide in diabetic patients. Eur J Clin Pharmacol. 1982;22:459-462.
56. Crooks MJ, Brown KF. The binding of sulphonylureas to serum albumin. J Pharm Pharmacol. 1974;26:304-311.
57. Brown KF, Crooks MJ. Displacement of tolbutamide, glibenclamide and chlorpropamide from serum albumin by anionic drugs. Biochem Pharmacol. 1976;25:1175-1178.
58. Lebovitz HE. Glipizide: a second-generation sulfonylurea hypoglycemic agent: pharmacology, pharmacokinetics and clinical use. Pharmacotherapy. 1985;5:63-77.
59. Groop L, Wåhlin-Boll E, Goop P-H, et al. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics. Eur J Clin Pharmacol. 1985;28:697-704.
60. Melander A, Lebovitz HE, Faber OK. Sulfonylureas: why, which, and how? Diabetes Care. 1990;13(suppl 3):18-25.
61. Ferner RE, Chaplin S. The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycemic drugs. Clin Pharmacokinet. 1987;12:379-401.
62. Bressler R. Adverse drug reactions in geriatric pharmacology. In: Bressler R, Kates MD, eds. Geriatric Pharmacology. New York, NY: McGraw-Hill Book Co; 1993:41-62.
63. Ferner RE, Neil HAW. Sulphonylureas and hypoglycaemia. BMJ. 1988;296:940-949.
64. Seltzer HS. Drug-induced hypoglycemia: a review of 1418 cases. Endocrinol Metab Clin North Am. 1989;18:163-183.
65. Snehalatha C, Ramachandran A, Mohan V, et al. Beta cell function in long term NIDDM (type 2) patients and its relation to treatment. Horm Metab Res. 1986;18:391-394.
66. Groop LC, Pelkonen R, Koskimies S, et al. Secondary failure to treatment with oral antidiabetic agents in non-insulin dependent diabetes. Diabetes Care. 1986;9:129-133.
67. Shen SW, Bressler R. Clinical pharmacology of oral antidiabetic agents. N Engl J Med. 1977; 296:493-496, 787-793.
68. Boyden T, Bressler R. Oral hypoglycemic agents. Adv Intern Med. 1979;24:53-70.
69. Singer DL, Hurwitz D. Long term experience with sulfonylureas and placebo. N Engl J Med. 1967;277:450-456.
70. UK prospective study of therapies of maturity-onset diabetes, I: effect of diet, sulphonlyurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year. Diabetologia. 1983;24:404-411.
71. Balodimos MC, Camerini-Davalos RA, Marble A. Nine years experience with tolbutamide in the treatment of diabetes. Metabolism. 1966; 15:957-970.
72. 1C with basal insulin supplement sulfonylurea or biguianidine therapy in maturity-onset diabetes: a multicenter study Diabetes. 1985; 34:793-798.
73. Muller R, Bauer G, Schroder R, et al. Summary report of clinical investigation of the oral antidiabetic drug HB 419 (glibenclamide). Horm Metab Res. 1969;1 (suppl):88-92.
74. Pontiroli AE, Calderara A, Pozza G. Secondary failure of oral hypoglycaemic agents: frequently, possible causes and management. Diabetes Metab Rev. 1994;10:31-43.
75. Turner RC, Holman RR, Matthews DR. Sulfonylurea failure and inadequacy. In: Cameron D, Colagiuri S, Heding L, et al, eds. Non-Insulin Dependent Diabetes Mellitus. Belle Mead, NJ: Excerpta Medica-Princeton; 1989: 52-55.
76. Yki-Järvinen H, Helve E, Koivisto VA. Hyperglycemia decreases glucose uptake in type I diabetes. Diabetes. 1987;36:892-896.
77. Garvey WT, Olefsky JM, Griffin J, et al. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985;34:222-234.
78. Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79:1510-1515.
79. UK Prospective Diabetes Group, Perspectives in Diabetes. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44: 1249-1258.
80. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin dependent diabetes mellitus. Ann Intern Med. 1996;124:136-145.
81. Holmes B, Heel RC, Brogden RN, et al. Gliclazide: a preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. Drugs. 1984;27:301-327.
82. Weissman PN, Shenkman L, Gregerman RI. Chlorpropamide hyponatremia: drug-induced inappropriate antidiuretic hormone activity. N Engl J Med. 1971;284:65-71.
83. Kadowaki T, Hagura R, Kajinuma H, et al. Chlorpropamide-induced hyponatremia: incidence and risk factors. Diabetes Care. 1983;6:468-471.
84. Moses AM, Numann P, Miller M. Mechanism of chlorpropamide-induced antidiuresis in man: evidence for release of ADH and enhancement of peripheral action. Metabolism. 1973;22:59-66.
85. Kadowaki T, Hagura R, Kajin H, et al. Chlorpropamide-induced hyponatremia: incidence and risk factors. Diabetes Care. 1983;6:468-471.
86. Jerntorp P, Aimer LO, Ohlin H, et al. Plasma Chlorpropamide: a critical factor in chlorpropamide-alcohol flush. Eur J Clin Pharmacol. 1983; 24:237-242.
87. Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care. 1989;12:203-208.
88. Berger W, Caduff F, Pasquel M, Rump A. Die relativ Häufigkeit der schweren Sulfonylharnstoff: Hypoglykämie in den letzen 25 Janren in der Schweiz. Schweiz Med Wochenschr. 1986; 116:145-151.
89. Asplund K, Wiholm B-E, Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia. 1983;24:412-417.
90. 14C-glyburide in patients with varying renal function. Clin Pharmacol Ther. 1986;39:318-324.
91. Berger W. Incidence of severe side effects during therapy with sulfonylureas and biguanides. Horm Metab Res. 1985;17(suppl 15): 111-115.
92. Widom B, Simonson DC. latrogenic hypoglycemia. In: Kahn CR, Weir GC, eds. Joslin's Diabetes Mellitus. 13th ed. Philadelphia, Pa: Lea & Febiger; 1994:489-507.
93. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: mortality results. Diabetes. 1970;19 (suppl 2):785-830.
94. Biometric Society. Report of Committee for Assessment of Biometric Agents of Controlled Trials of Hypoglycemic Agents. JAMA. 1975;231: 583-608.
95. Kilo C, Miller JP, Williams JR. Crux of UGDP: spurious results and biologically inappropriate data analysis. Diabetologia. 1980;18:179-185.
96. Feinstein AR. How good is the statistical evidence against oral hypoglycemic agents? Adv Intern Med. 1979;24:71-95.
97. American Diabetes Association. Policy statement: UGD controversy. Diabetes. 1979;28: 168-170.
98. Balant L. Clinical pharmacokinetics of sulfonyl-urea hypoglycemic drugs. Clin Pharmacokinet. 1981;6:215-241.
99. Hansen M, Christensen LK. Drug interactions with oral sulphonylurea hypoglycaemic drugs. Drugs. 1977;13:24-34.
100. Johnson DG, Bressler R. New pharmacologic approaches. In: Rifkin H, Porte D Jr, eds. Diabetes Mellitus: Theory and Practice. New York, NY: Elsevier Science Inc; 1990:887-895.
101. Trischitta V, Italia S, Borzi V, et al. Low-dose bedtime NPH insulin in treatment of secondary failure to glyburide. Diabetes Care. 1989; 12:582-585.
102. Scheen A, Lefebvre PJ. Insulin versus insulin plus sulfonylureas in type 2 diabetic patients with secondary failure to sulfonylureas. Diabetes Res Clin Pract. 1989;6:S33-S43.
103. Groop LC, Groop P-H, Stenman S. Combined insulin-sulfonylurea therapy in treatment of NIDDM. Diabetes Care. 1990;13(suppl 3):47-52.
104. Lebovitz HE, Pasmantier RM. Combination insulin sulfonylurea therapy. Diabetes Care. 1990; 13:667-675.
105. Bailey TS, Mezitis NHE. Combination therapy with insulin and sulfonylureas for type II diabetes. Diabetes Care. 1990;13:687-695.
106. Del Prato S, Vigili de Kreutzenberg S, Riccio A, et al. Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents. Diabetologia. 1990;33:688-695.
107. Peters AL, Davidson MB. Insulin plus a sulfonylurea agent for treating type 2 diabetes. Ann Intern Med. 1991;115:45-53.
108. Yki-Järvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1992;327:1426-1454.
109. Chow C-C, Tsang LWW, Sorensen JP, et al. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care. 1995;18:307-314.
110. Campbell P, Bolli G, Cryer P, et al. Pathogenesis of the 'dawn phenomenon' in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1985;312:1473-1479.
111. Bohli G, Gerich J. The 'dawn phenomenon': a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med. 1984;31:746-750.
112. DeFronzo RA, Ferrannini E. Regulation of hepatic glucose metabolism in humans. Diabetes Metab Rev. 1987;3:415-459.
113. Riddle MC, Hart JS, Bouma DJ, et al. Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects. Diabetes Care. 1989;12:623-629.
114. Taskinen M-R, Sane T, Helve E, et al. Bedtime insulin for suppression of overnight free-fatty acid blood glucose and glucose production in NIDDM. Diabetes. 1989;38:580-588.
115. Clarke BF, Duncan LJP. Combined metforminchlorpropamide therapy in 108 diabetic sulphonylurea failures. Lancet. 1965;1:1248-1251.
116. Hermann LS. Biguanides and sulfonylureas as combination therapy in NIDDM. Diabetes Care. 1990;13(suppl 3):37-41.
117. Vigneri R, Goldfine ID. Role of metformin in treatment of diabetes mellitus. Diabetes Care. 1987;10:118-122.
118. Herman L, Scherstén B, Bitzén PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. Diabetes Care. 1994;17:1100-1109.
119. Dimitriadis G, Hatziagellaki E, Alexopoulos E, et al. Effects of α-glucosidase tolerance and timing of insulin administration in patients with type I diabetes mellitus. Diabetes Care. 1991;14: 393-398.
120. Schnack E, Prager RJF, Winkler J, et al. Effects of an 8-week α-glucosidase inhibition on metabolic control, C peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients. Diabetes Care. 1989;12:537-543.
121. Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in diabetes mellitus. Drugs. 1995;49:721-749.
122. Bailey CJ. Metformin: an update. Gen Pharmacol. 1993;24:1299-1309.
123. Garber AJ. Metformin therapy for type II diabetes mellitus. Pharmacol Ther. 1995;20:568-583.
124. Chow MSS. Focus on metformin. Formulary. 1995;30:383-387.
125. DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:541-549.
126. Hermann LS, Melander A. Biguanides: basic aspects and clinical uses. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. International Textbook of Diabetes Mellitus. New York, NY: Wiley & Sons Inc; 1994:773-795.
127. Sirtori C, Franceschini G, Galli-Kienle M, et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther. 1978;24: 683-693.
128. Pentikainen PJ. Bioavailability of metformin: comparison of solution, rapidly dissolving tablet, and three sustained release products. Int J Clin Pharmacol Ther Toxicol. 1986;24:213-220.
129. Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol. 1979;16:195-202.
130. Tucker GT, Casey C, Phillips PJ, et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981;12:235-246.
131. Assan R, Heuclin C, Ganeval D, et al. Metformin-induced lactic acidosis in the presence of acute renal failure. Diabetologia. 1977;13:211-217.
132. Hutchison SMW, Catterall JR. Metformin and lactic acidosis: a reminder. Br J Clin Pact. 1987; 41:673-674.
133. Lucis OJ. The status of metformin in Canada. Can Med Assoc J. 1983;128:24-26.
134. Clarke BF, Duncan LJP. Biguanide treatment in the management of insulin independent (maturity-onset) diabetes: clinical experience with metformin. Res Clin Forums. 1979;1:53-63.
135. Phillips PJ, Scicchitano R, Clarkson AR, et al. Metformin associated lactic acidosis. Aust N Z J Med. 1978;8:281-284.
136. Lalau JD, Lacroix C, Compagnon P, et al. Role of metformin accumulation in metforminassociated lactic acidosis. Diabetes Care. 1995; 18:779-784.
137. Wilcock C, Bailey CJ. Sites of metformin-stimulated glucose metabolism. Biochem Pharmacol. 1990;39:1831-1834.
138. Bailey CJ, Wilcock C, Day C. Effect of metformin on glucose metabolism in the splanchnic bed. Br J Pharmacol. 1992;105:1009-1015.
139. Campbell IW. Metformin and the sulphonylureas: the comparative risk. Horm Metab Res. 1985;15:105-111.
140. Lalau JD, Andrejak M, Moniniere P, et al. Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination. Int J Clin Pharmacol Ther Toxicol. 1989;27:285-288.
141. Shenfield GM, Bhalla IP, Steel JM, et al. Metformin in the treatment of obese diabetics. Practitioner. 1977;219:745-749.
142. Clarke BF, Duncan LPJ. Comparison of chlorpropamide and metformin treatment on weight and blood-glucose response of uncontrolled obese diabetics. Lancet. 1968;1:123-126.
143. Lim P, Khoo OT. Metformin compared with tolbutamide in the treatment of maturity-onset diabetes mellitus. Med J Aust. 1970;1:271-273.
144. Siitonen O, Aro A, Huttunen JK, et al. Effect of discontinuation of biguanide therapy on metabolic control in maturity-onset diabetics. Lancet. 1980;1:217-220.
145. Clarke BF, Campbell IW. Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet. BMJ. 1977;2:1576-1578.
146. Hermann LS. Metabolic effects of metformin in relation to clinical effects and side effects. J R Soc Med. 1984;48:3-13.
147. Dornan TL, Heller SR, Peck GM, et al. Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care. 1991;14: 342-324.
148. Josephkutty S, Potter JM. Comparison of tolbutamide and metformin in elderly diabetic patients. Diabet Med. 1990;7:510-514.
149. Elkeles RS. The effects of oral hypoglycemic drugs on serum lipids and lipoproteins in non-insulin-dependent diabetes (NIDDM). Diabete Metab. 1991;17:197-200.
150. Hermann LS, Bitzen PO, Kjellstrom T, et al. Comparative efficacy of metformin and glibenclamide in patients with non-insulin-dependent diabetes mellitus. Diabete Metab. 1991;17:201-208.
151. Higginbotham L, Martin FIR. Double-blind trial of metformin in the therapy of non-ketotic diabetics. Med J Aust. 1979;2:154-156.
152. Noury J, Nandeuil A. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDDM. Diabete Metab. 1991;17:209-212.
153. Clarke BF, Marshall A, McGill RC, et al. A 3-year evaluation of combined sulphonylurea-metformin treatment in 200 diabetic ketoacidosis resistant sulphonylurea failures. In: Butterfield WJH, van Westering W, eds. Tolbutamide . . . After Ten Years. Belle Mead, NJ: Excerpta Medica-Princeton; 1967:312-320.
154. Nattrass M, Hinks L, Smythe P, et al. Metabolic effects of combined sulphonylurea and metformin therapy in maturity-onset diabetics. Horm Metab Res. 1979;11:332-337.
155. Capretti L, Bonora E, Coscelli C, et al. Combined sulphonylurea-biguanide therapy for non-insulin-dependent diabetics: metabolic effects of glibenclamide and metformin or phenformin in newly diagnosed obese patients. Curr Med Res Opin. 1982;7:677-683.
156. Reaven GM, Johnston P, Hollenbeck CB, et al. Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab. 1992;74:1020-1026.
157. Haupt E, Knick B, Koschinsky T, et al. Oral antidiabetic combination therapy with sulfonylureas and metformin. Diabete Metab. 1991;17: 224-231.
158. Trischitta V, Italia S, Mazzarino S, et al. Comparison of combined therapies in treatment of secondary failure to glyburide. Diabetes Care. 1992;15:539-542.
159. Hother-Nielsen O, Schmitz O, Andersen PH, et al. Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinol. 1989;120:257-265.
160. Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care. 1990;13:696-704.
161. DeFronzo RA, Barzilai N, Simonsen DC. Mechanism of metformin action in obese and lean non-insulin-dependent diabetic subjects. J Clin Endocrinol Metab. 1991;73:1294-1301.
162. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995; 333:550-554.
163. Bailey CJ. Biguanides and NIDDM. Diabetes Care. 1992;15:755-772.
164. Nosadini R, Avogaro A, Trevisian R, et al. Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes. Diabetes Care. 1987;10:62-67.
165. Jeppesen J, Zhou MY, Chen YDI, et al. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care. 1994;17:1093-1098.
166. Sirtori CR, Weber G, Losi M, et al. Metformin and lipid metabolism. Res Clin Forums. 1979; 1:117-122.
167. Wu MS, Johnston P, Sheu WHH, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care. 1990;13:1-8.
168. Collier A, Watson HH, Patrick AW, et al. Effect of glycaemic control metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabete Metab. 1989;15:420-425.
169. Genuth S. Management of the adult onset diabetic with sulfonylurea drug failure. Endocrinol Metab Clin North Am. 1992;21:351-371.
170. Howard BV, Howard WJ. Dyslipidemia in non-insulin-dependent diabetes mellitus. Endocr Rev. 1994;15:263-274.
171. Marena S, Taglaferro V, Montegrosso, et al. Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes. Diabete Metab. 1994;20:15-19.
172. Stowers JM, Borthwick LJ. Oral hypoglycaemic drugs: clinical pharmacology and therapeutic use. Drugs. 1977;14:41-47.
173. Menzies DG, Campbell IW, McBain A, et al. Metformin efficacy and tolerance in obese non-insulin dependent diabetics: a comparison of two dosage schedules. Curr Med Res Opin. 1989; 11:273-278.
174. Dandona P, Fonseca V, Mier A, et al. Diarrhea and metformin in a diabetic clinic. Diabetes Care. 1983;6:472-474.
175. Pagano G, Tagliaferro V, Carta Q, et al. Metformin reduces insulin requirement in type 1 (insulin-dependent) diabetes. Diabetologia. 1983; 24:351-354.
176. Colca JR, Morton DR. Antihyperglycaemic thiazolidinediones: ciglitazone and its analogues. In: Bailey CJ, Flatt PR, eds. New Antidiabetic Drugs. London, England: Smith Gordon; 1990:255-261.
177. Fujlwara T, Yoshioka S, Yoshioka T, et al. Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 1988;37:1549-1558.
178. Ciarladi TP, Gilmore A, Olefsky J, et al. In vitro studies on the action of CS-045: a new antidiabetic agent. Metabolism. 1990;39:1056-1062.
179. Steiner KE, Lien EL. Hypoglycaemic agents which do not release insulin. Prog Med Chim. 1987; 24:209-248.
180. Chang AY, Wyse BM, Gilchrist BJ. Ciglitazone: a new hypoglycemic agent, I: studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats. Diabetes. 1983;32:830-838.
181. Sugiyama Y, Taketomi S, Shimura Y, et al. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats. Arzneim Forsch. 1990;40:263-267.
182. Whitcomb RW, Saltiel AR. Section review: oncologic, endocrine & metabolic: thiazolidine-diones. Exp Opin Invest Drugs. 1995;4:1299-1309.
183. Kuehnle HF. New therapeutic agents for the treatment of NIDDM. Exp Clin Endocrinol Diabetes. 1996;104:93-101.
184. Fujiwara T, Okuno A, Yoshioka S. Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism. 1995;44:486-490.
185. Müller HK, Kellerer M, Ermel B. Prevention by protein kinase inhibitors of glucose-induced insulin-receptor tyrosine kinase resistance in rat fat cells. Diabetes. 1991;40:1440-1447.
186. Kellerer M, Kroder G, Tittmer S, et al. Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes. 1994;43:447-453.
187. Ciaraldi TP, Huber K, Hickman M, et al. Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents. Metabolism. 1995;44:976-982.
188. Suter SL, Nolan JJ, Wallace P, et al. Metabolic effects of new and hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 1992; 15:193-203.
189. Iwamoto Y, Kuzuya T, Matsuda A, et al. Effects of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care. 1991;14: 1083-1086.
190. Hofmann CA, Colca JR. New oral thiazolidine-dione antidiabetic agents act as insulin sensitizers. Diabetes Care. 1992;15:1075-1078.
191. Kosaka K, Kuzuya T, Akanuma Y, et al. Clinical evaluation of a new oral hypoglycemic drug CS-0045 in patients with non-insulin-dependent diabetes poorly controlled by sulfonylureas: a double-blind placebo controlled study. J Clin Ther Med. 1993;9(suppl 3):95-126.
192. Kuzuya T, Iwamoto Y, Kosaka K, et al. A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1991; 11:147-154.
193. Onuma T, Tsutsui M, Goto T, et al. The effect of a new oral hypoglycemic drug, CS-045, on glucose tolerance and serum lipids in non-obese Japanese patients with non-insulin-dependent diabetes mellitus: a pilot study. Curr Ther Res. 1994;55:416-421.
194. Kumar S, Boulton AJM, Beck-Nielsen H, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia. 1996;39:701-709.
195. Mimura K, Umeda F, Hiramatsu S, et al. Effects of a new oral hypoglycemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabet Med. 1994; 11:685-691.
196. Iwanmoto Y, Kosaka K, Kuzuya T, et al. Effect of combination therapy of troglitazone and sulfonylureas in patients with type 2 diabetes who were poorly controlled by sulfonylurea therapy alone. Diabet Med. 1996;13:365-370.
197. Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994;331:1188-1193.
198. Jenkins DJA, Wolever TMS, Vuksan V, et al. Nibbling versus gorging: metabolic advantages of increased meal frequency. N Engl J Med. 1989;321:929-934.
199. Jenkins DJA, Wolever TMS, Ocana AM, et al. Metabolic effects of reducing rate of glucose ingestion by single bolus versus continuous sipping. Diabetes. 1990;39:775-781.
200. Taylor RH. Alpha-glucosidase inhibitors. In: Bailey CJ, Flatt PR, eds. New Antidiabetic Drugs. London, England: Smith-Gordon; 1990:119-132.
201. Schmidt DD, Frommer W, Junge B, et al. α-Glucosidase inhibitors: new complex oligosaccharides of microbial origin. Naturwissenschatten. 1977; 64:535-536.
202. Puls W, Keup U, Krause HP, et al. Glucosidase inhibition: a new approach to the treatment of diabetes, obesity, and hyperlipoproteinaemia. Naturwissenschaften. 1977;64:536-537.
203. Caspary WF. Severe malabsorption in man after ingestions of α-glucosidehydrolase inhibitor. Lancet. 1978;1:1231-1233.
204. Hillebrand I, Boehme K, Frank G, et al. The effects of the α-glucosidase inhibitor BAYg 5421 (acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man. Res Exp Med. 1979;175:81-86.
205. Hillebrand I, Boehme K, Frank G, et al. The effects of the α-glucosidase inhibitor BAYg 5421 (acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: dose-time-response relationships in man. Res Exp Med. 1979;175:87-94.
206. Joubert PH, Venter HL, Foukaridis GN. The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism? Br J Clin Pharmacol. 1990;30:391-396.
207. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multi-center controlled clinical trial. Ann Intern Med. 1994;121:928-935.
208. Hanefeld M, Fischer S, Schulze J, et al. Therapeutic potentials of
209. Vierhapper H, Bratusch-Marrain A, Waldausl W. α-Glucoside hydrolase inhibition in diabetes. Lancet. 1978;2:1386.
210. Walton RJ, Sherif IT, Noy GA, et al. Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucosidehydrolase inhibitor. BMJ. 1979;1:220-221.
211. Requejo F, Uttenthal LO, Bloom SR. Effects of alphaglucosidase inhibition and viscous fibre on diabetic control and postprandial gut hormone responses. Diabet Med. 1990;7:515-520.
212. Tuomilehto J. Acarbose monotherapy in the treatment of non-insulin dependent diabetes mellitus: a review. In: Creutzfeldt W, ed. Acarbose for the Treatment of Diabetes Mellitus: 2nd International Symposium on Acarbose. New York, NY: Springer-Verlag NY Inc; 1988:104-118.
213. Lebovitz HE. Oral antidiabetic agents: the emergence of α-glucosidase inhibitors. Drugs. 1992; 44(suppl 3):21-28.
214. International Symposium on Acarbose. New York, NY: Springer-Verlag NY Inc; 1988:29-38.
215. Jenkens DJA, Taylor RH, Nineham R, et al. Combined use of guar and acarbose in reduction of postprandial glycaemia. Lancet. 1979;2:924-927.
216. Sachse G. Acarbose in non-insulin-dependent diabetes: long-term studies in combination with oral agents. In: Creutzfeldt W, ed. Acarbose for the Treatment of Diabetes Mellitus: 2nd International Symposium on Acarbose. New York, NY: Springer-Verlag NY Inc; 1988:92-103.
217. Peters A, Davidson M. Insulin plus a sulfonylurea agent for treating type 2 diabetes. Ann Intern Med. 1991;114:45-53.
218. Pugh J, Wagner ML, Sawyer J, et al. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? Diabetes Care. 1992; 15:853-959.
219. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy In type II diabetes. Arch Intern Med. 1996;156: 259-264.
220. Riddle M, Hart J, Bouma D, et al. An effective new regimen for type II diabetes: bedtime insulin with daytime sulfonylurea. Diabetes. 1986; 35(suppl):263. Abstract.
221. Groop L, Widen E. Treatment strategies for secondary sulfonylurea failure. Diabete Metab. 1991; 17:218-213.
222. Vigneri R, Trischitta V, Italia S, et al. Treatment of NIDDM patients with secondary failure to glyburide: comparison of the addition of either metformin or bed-time NPH insulin to glyburide. Diabete Metab. 1991;17:232-234.
223. Soneru IL, Agrawal L, Murphy JC, et al. Comparison of morning or bedtime insulin with and without glyburide in secondary sulfonylurea failure. Diabetes Care. 1993;16:896-901.
224. Landsted-Hallin L, Adamson U, Arner P, et al. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care. 1995; 18:1183-1186.
225. Chow CC, Tsang LW, Sorensen JP, et al. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care. 1995;18:307-314.
226. Quatraro A, Giugliano O. The combination of insulin and oral hypoglycemic drugs: a continuous challenge. Diabete Metab. 1993;19:219-224.
227. Giugliano D, Quatraro A, Consoli G, et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol. 1993;44:107-112.
228. Golay A, Guillet-Dauphine N, Fendel A, et al. The insulin-sparing effect of metformin in insulin-treated diabetic patients. Diabetes Metab Rev. 1995;11(suppl 1):S63-S67.
229. Aguilar CA, Wong B, Gomez-Perez FJ, et al. Combination daytime chlorpropamide-metformin/bedtime insulin in the treatment of secondary failures in non-insulin dependent diabetes. Rev Invest Clin. 1992;44:71-76.
230. diCianni G, Benzi L, Ciccarone AM, et al. Bed-time NPH-insulin plus combined sulfonylurea-biguanide oral therapy for treating refractory non-insulin dependent diabetic patients. Diabete Metab. 1992;18:468-469.
231. Reaven GM. Syndrome X. Clin Diab. 1994;32-36.
232. Steinman S, Mellander A, Groop P-H, et al. What is the benefit of increasing the sulfonylurea dose? Ann Intern Med. 1993;118:169-172.
233. Glimepiride for NIDDM. Med Lett. 1996;38:47-48.
234. Draeger E. Clinical profile of glimepiride. Diabetes Res Clin Pract. 1995;28(suppl):139-146.